Novartis AG

Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry (2025) Oommen PT, Kallinich T, Rech J, Blank N, Weber-Arden J, Kuemmerle-Deschner JB Journal article, Original article Automated Multicohort Mobility Assessment with an Instrumented L-test (iL-test) (2025) Albites-Sanabria J, Palumbo P, D'ascanio I, Bonci T, Caruso M, Salis F, Cereatti A, et al. Journal article Evaluating the Accuracy and Reliability of Real-World Digital Mobility Outcomes in Older Adults After Hip Fracture: Cross-Sectional Observational Study (2025) Berge MA, Paraschiv-Ionescu A, Kirk C, Küderle A, Micó-Amigo E, Becker C, Cereatti A, et al. Journal article Estimating Group Means Under Local Differential Privacy (2025) Raab R, Bohr A, Klede K, Gmeiner B, Eskofier B Journal article Corrigendum to “Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations” [Eur J Cancer 207 (2024) 114158](S0959804924008141)(10.1016/j.ejca.2024.114158) (2024) Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, et al. Journal article, Erratum Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer (2024) Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann FT, Rody A, Schneeweiss A, et al. Journal article Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device (2024) Kirk C, Küderle A, Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Soltani A, et al. Journal article Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations (2024) Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, et al. Journal article Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study (2024) Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, et al. Journal article 177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024) Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel ME, Kunz PL, Chasen B, et al. Journal article